A cutting edge technology and significant opportunity for growth

Presbia Acquires Comprehensive Patent Portfolio for the Presbia Flexivue Microlens™

<<  Back
Presbia Acquires Comprehensive Patent Portfolio for the Presbia Flexivue Microlens™

Now the only corneal implant company with intellectual property for near-vision correction with a powered micro-lens

DUBLIN--(BUSINESS WIRE)-- Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that on August 2, 2016, its wholly-owned subsidiary, Presbia Ireland, Ltd., completed the purchase of the assets of Neoptics AG ("Neoptics"), including its intellectual property portfolio.

"The acquisition of Neoptics' assets, including its patent portfolio, consolidates the principal intellectual property (‘IP') and ‘know-how' underpinning the use of an optically powered micro-lens for the correction of presbyopia (near-vision loss), a condition affecting 1.8 billion people globally. This consolidation of IP and know-how from Presbia and Neoptics has also created a patent protected platform to deploy our ‘micro-lens' technology into solutions for vision problems beyond presbyopia, significantly expanding our addressable market into the future," said Todd Cooper, President and CEO of Presbia.

Forward-Looking Statements

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release, and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties, including, but not limited to, the factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

Presbia PLC
Monica Yamada, 323-860-4903
[email protected]

Source: Presbia PLC

News Provided by Acquire Media